New concepts in superovulation strategies for assisted conception treatments

被引:9
作者
Salha, O [1 ]
Balen, AH [1 ]
机构
[1] Leed Gen Infirm, Dept Reprod Med, Leeds LS2 9NS, W Yorkshire, England
关键词
D O I
10.1097/00001703-200006000-00007
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Controlled ovarian stimulation for in-vitro fertilization treatment using preparations that contain follicle-stimulating hormone has been routinely performed since the 1980s. The early preparations were urinary human menopausal gonadotrophins, containing follicle-stimulating hormone and luteinizing hormone. In the early 1990s, highly purified follicle-stimulating hormone preparations were introduced because of a desire to provide drugs for subcutaneous administration with a lower risk of allergic reactions. intensive research resulted in the discovery of recombinant follicle-stimulating hormone, which is more potent that the highly purified follicle-stimulating hormone, resulting in significantly higher clinical pregnancy rates. The two recombinant follicle-stimulating hormone preparations available appear to be equally effective and provide comparable results. Gonadotrophin-releasing hormone antagonists, which have recently been introduced, appear to be effective in preventing a premature rise in luteinizing hormone during ovarian stimulation for in-vitro fertilization, as well as improved response to lower doses of gonadotrophins, It is envisaged that the availability of recombinant gonadotrophins and gonadotrophin-releasing hormone antagonists will ultimately lead to shorter, cheaper and safer treatments, using reduced dosages. (C) 2000 Lippincott Wiillams & Wilkins.
引用
收藏
页码:201 / 206
页数:6
相关论文
共 51 条
[1]  
Albano C, 1996, HUM REPROD, V11, P1632
[2]   Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation [J].
Albano, C ;
Smitz, J ;
Camus, M ;
RiethmullerWinzen, H ;
VanSteirteghem, A ;
Devroey, P .
FERTILITY AND STERILITY, 1997, 67 (05) :917-922
[3]  
[Anonymous], 1998, Hum Reprod, V13, P3023
[4]  
[Anonymous], 1995, Fertil Steril, V63, P77
[5]  
BAIRD TD, 1999, EVIDENCE BASED FERTI, P274
[6]   Assisted reproduction-in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin-releasing hormone analogues [J].
Barbieri, RL ;
Hornstein, MD .
ENDOCRINE REVIEWS, 1999, 20 (03) :249-252
[7]  
Bennink HJTC, 1998, FERTIL STERIL, V69, P19
[8]   Recombinant human follicle stimulating hormone (r-hFSH; Gonal-F®) versus highly purified urinary FSH (Metrodin HP®):: results of a randomized comparative study in women undergoing assisted reproductive techniques [J].
Bergh, C ;
Howles, CM ;
Borg, K ;
Hamberger, L ;
Josefsson, B ;
Nilsson, L ;
Wikland, M .
HUMAN REPRODUCTION, 1997, 12 (10) :2133-2139
[9]  
BILSKA S, 1999, HUM REPROD, V14, P2391
[10]   A comparison of the efficacy and tolerability of two recombinant human follicle-stimulating hormone preparations in patients undergoing in vitro fertilization-embryo transfer [J].
Brinsden, P ;
Akagbosu, F ;
Gibbons, LM ;
Lancaster, S ;
Gourdon, D ;
Engrand, P ;
Loumaye, E .
FERTILITY AND STERILITY, 2000, 73 (01) :114-116